---
title: "AstraZeneca jumps 5% after report rules out BMS merger talks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294975462.md"
description: "AstraZeneca climbed 5% during regular trading after Reuters reported no active merger talks with Bristol-Myers Squibb."
datetime: "2026-08-05T13:33:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294975462.md)
  - [en](https://longbridge.com/en/news/294975462.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294975462.md)
---

# AstraZeneca jumps 5% after report rules out BMS merger talks

阿斯利康 (AZN.US) 盘中急涨，截至发稿涨 5.15%，现报 163.64 美元。

据路透社消息，目前阿斯利康与百时美施贵宝之间并无正在进行的合并谈判，该消息推动股价走高。

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [FACTBOX-Global drugmakers invest billions to boost US presence](https://longbridge.com/en/news/295412790.md)
- [Why Is Bristol-Myers Squibb Stock Surging Monday?](https://longbridge.com/en/news/294697898.md)
- [Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296196164.md)
- [Asia Distillates-Diesel timespreads, cash premiums ease as markets eye more Sept activity](https://longbridge.com/en/news/296085019.md)
- [Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)](https://longbridge.com/en/news/294716282.md)